Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
March 22 2022 - 4:06PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today that AVISE® tests
will soon surpass 90 million lives as an in-network benefit for
patients. Effective June 1, 2022, AVISE test offerings become an
in-network, covered benefit with Centene Corporation, including its
subsidiary WellCare Health Plans, providing enhanced care to over
22.7 million members.
“Exagen continues to expand its presence within the payor
community. The partnership with Centene and WellCare, combined with
our existing partners, will allow for over 90 million patients to
receive AVISE testing as an in-network benefit, to enable a timely
and accurate differential diagnosis to improve outcomes for complex
autoimmune diseases, including SLE,” said Ron Rocca, Exagen’s
President and CEO. “SLE is an unpredictable and misunderstood
disease that ravages different parts of the body. It is difficult
to diagnose, hard to live with, a challenge to treat, and can be
fatal.”
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this press release
regarding matters that are not historical facts are forward-looking
statements. These statements are based on Exagen's current beliefs
and expectations. Such forward-looking statements include, but are
not limited to, statements regarding the expected benefits of the
positive medical policy coverage for the AVISE CTD test with
Centene Corporation, including the availability and expected use of
the AVISE CTD test through the Centene network, and any potential
for increased use of the AVISE CTD laboratory test. The inclusion
of forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: the COVID-19 pandemic may
continue to adversely affect our business, financial condition and
results of operations, including as a result of shutdowns of its
facilities and operations as well as those of its suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests, its sales and
commercialization activities and its ability to receive specimens
and perform or deliver the results from its tests, and delays in
ongoing and planned clinical trials involving its tests; Exagen’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payors
and others in the medical community; Exagen’s ability to
successfully execute on its business strategies; third party payors
not providing coverage and adequate reimbursement for Exagen’s
testing products or promoted therapeutics; Exagen’s ability to
obtain and maintain intellectual property protection for its
testing products; regulatory developments affecting Exagen’s
business; and other risks described in the company’s prior press
releases and Exagen’s filings with the Securities and Exchange
Commission (SEC), including under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended December
31, 2021 and any subsequent filings with the SEC. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and Exagen undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024